STATERA THERAPEUTICS, Inc. | c/o Health Haven Hub | 195 Church Street, 9th Floor | New Haven CT 06510

The Problem

Patients who suffer from autoimmune disease accept chronic management of symptoms through nonspecific immunosuppressant as the standard of treatment. These treatments along with medications ranging from cyclophosphamide to biologic therapies are associated with an increased risk for infections as well as significant adverse effects including hepatotoxicity, gastrointestinal perforation, and fatigue.

 

An optimal treatment strategy for autoimmune disease would specifically target disease associated antigens and limit systemic side effects. Many recent approaches have focused on the development of curative, antigen specific immunotherapies (ASI); however, the market has seen little clinical success. Promising animal studies of ASI have not yet been translated into clinical efficacy.

 

As such, world-leading immunologists have voiced that a new delivery mechanism that maximizes efficacy is necessary to push the first antigen-specific therapy through FDA approval.

 

Our Solution

An engineered nanoparticle that delivers dual therapeutic agents to the right place at the right time.

 

Because of the spatial and temporal control, we achieve better results in addition to lowering concentration, frequency, and side effects.

Spatiotemporally Tuned Particles

(STPs)

 

Statera’s patented technology, Spatiotemporally Tuned Particles (STP), adds targeting and temporal control to the otherwise free floating drug agents. In encapsulating drug agents in STP, we can achieve optimized, sequential delivery to specific cell targets. STP has been shown to supersede the efficacy of the current standard of combinatorial drug delivery in multiple sclerosis disease model by as much as 150% in both treatment and prevention. It also increases the bioavailability of these agents, leading to reduction in dosage frequency and in side effects.

Overall, we are able to take an existing, or potentially failed, target antigen(s), and increase its efficacy through encapsulation in STP. In essence, we can rescue shelved antigens that failed due to a lack of clinical efficacy. In addition, we are working toward encapsulation of protein libraries as a way to side step of the problem of having to find the “right” antigen, which is often a critical pitfall that many antigen specific therapy companies encounter. Our STP platform is the key to unlock the true potential of antigen-specific therapy.

Meet Our Team

 

Philip Kong, PhD

  • Grey LinkedIn Icon

A PhD in Immunology from Yale, and a Fulbright Scholar from Cal Tech. Philip has published scientific papers in top-tier journals, such as Cell Host and Microbe.

Professor Tarek Fahmy

  • Grey LinkedIn Icon

A tenured Yale professor in biomedical engineering focused on nanoparticle platform technology development,Dr. Fahmy is also a serial entrepreneur who has founded 5 successful ventures.

Sean Bickerton, MD/PhD

  • Grey LinkedIn Icon

A MD/PhD candidate at Yale with background in chemistry, drug delivery, and immunotherapy. Sean has published in Journal of the American Chemical Society and Journal of Clinical Investigation.

Jen Fischer, MBA

  • Grey LinkedIn Icon

A data analytics professional with background in healthcare, Jennifer attended Yale School of Medicine and earned her MBA from Yale School of Management.

Owen Yang, MBA

  • Grey LinkedIn Icon

A healthcare and life science professional with background in private equity. Obtained his MBA from Yale School of Management.

CONTACT US

Have a question about our technology? Interested in a possible partnership? Want to join our team?

Reach out below.